Evidence map›Paper›PMID 29288266›Full record

ArticleInvestigative ophthalmology & visual science2017

Mitochondrial Haplogroups Modify the Effect of Diabetes Duration and HbA1c on Proliferative Diabetic Retinopathy Risk in Patients With Type 2 Diabetes.

Sabrina L Mitchell, Abigail C Neininger, Carleigh N Bruce, Isaac M Chocron, Jana A Bregman, Christopher B Estopinal, Ayesha Muhammad, Allison C Umfress, Kelli L Jarrell, Cassandra Warden and 4 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sabrina L MitchellVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Abigail C NeiningerVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Carleigh N BruceVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Isaac M ChocronVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Jana A BregmanVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Christopher B EstopinalVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Ayesha MuhammadVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Allison C UmfressVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Kelli L JarrellVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Cassandra WardenVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Paula A HarlowVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Melissa WellonsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
David C SamuelsVanderbilt Genetics Institute and Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States.
Milam A BrantleyVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Vanderbilt Genome-Electronic Records ProjectU01HG004603 · NHGRI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2007 to 2011
$7.3M
VESPA: Vanderbilt Electronic Systems for Pharmacogenomic AssessmentRC2GM092618 · NIGMS · VANDERBILT UNIVERSITY · PI DENNY, JOSHUA C., RODEN, DAN M · 2009 to 2010
$6.4M
Vanderbilt Student Research Training ProgramT35DK007383 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI William Heerman · 1986 to 2026
$4.1M
Metabolomic and Genetic Interactions in Age-Related Macular DegenerationR01EY022618 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRANTLEY, MILAM A · 2013 to 2017
$2.3M
NCATS NIH HHS UL1 TR000445NEI NIH HHS R01 EY022618NHGRI NIH HHS U01 HG004603NIDDK NIH HHS T35 DK007383NIGMS NIH HHS RC2 GM092618NIGMS NIH HHS T32 GM007347
6 · The paper itself

Abstract

Purpose: We previously demonstrated an association between European mitochondrial haplogroups and proliferative diabetic retinopathy (PDR). The purpose of this study was to determine how the relationship between these haplogroups and both diabetes duration and hyperglycemia, two major risk factors for diabetic retinopathy (DR), affect PDR prevalence. Methods: Our population consisted of patients with type 2 diabetes with (n = 377) and without (n = 480) DR. A Kruskal-Wallis test was used to compare diabetes duration and hemoglobin A1c (HbA1c) among mitochondrial haplogroups. Logistic regressions were performed to investigate diabetes duration and HbA1c as risk factors for PDR in the context of European mitochondrial haplogroups. Results: Neither diabetes duration nor HbA1c differed among mitochondrial haplogroups. Among DR patients from haplogroup H, longer diabetes duration and increasing HbA1c were significant risk factors for PDR (P = 0.0001 and P = 0.011, respectively). Neither diabetes duration nor HbA1c was a significant risk factor for PDR in DR patients from haplogroup UK. Conclusions: European mitochondrial haplogroups modify the effects of diabetes duration and HbA1c on PDR risk in patients with type 2 diabetes. In our patient population, longer diabetes duration and higher HbA1c increased PDR risk in patients from haplogroup H, but did not affect PDR risk in patients from haplogroup UK. This relationship has not been previously demonstrated and may explain, in part, why some patients with nonproliferative DR develop PDR and others do not, despite similar diabetes duration and glycemic control.

Indexed as

Polymorphism, Single NucleotideAgedBlood GlucoseCase-Control StudiesDiabetes Mellitus, Type 2Diabetic RetinopathyDNA, MitochondrialFemaleGlycated HemoglobinHaplotypesHumansMaleMitochondriaRisk FactorsUnited StatesWhite PeopleBlood GlucoseDNA, MitochondrialGlycated Hemoglobin

Identifiers

PMID29288266
PMCPMC5749245
OpenAlexW2777767804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.